Resilience in East Asian Immigrants for Advance Care Planning Discussions
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- University of Illinois at Chicago
- Study ID
- NCT06035549
- Status
- Recruiting
Conditions
- Advance Care Planning
- Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Culturally Tailored Digital Resilience-Building — BEHAVIORALThe Culturally Tailored Digital Resilience-Building materials include an introduction to advance care planning and resilience skills that specifically address cultural beliefs and barriers.
- Semi-structured interviews — BEHAVIORALSemi-structured interviews with religious leaders who provide spiritual care to Asian Americans/immigrants.
Study Details
The purpose of the study is to develop a culturally tailored digital resilience-building intervention to help East Asian immigrants engage in advance care planning discussions with their family caregivers.
Key Dates
- Start date
- Oct 27, 2023
- Status verified
- Jan 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 84 participants (estimated)
Arms
- Arm: Culturally Tailored Digital Resilience-BuildingThe culturally tailored resilience-building materials will be provided to East Asian immigrants with cancer and their family caregivers.
- Arm: Religious leadersReligious leaders providing spiritual care to Asian Americans
Primary Outcome Measure
Usability [ Time Frame: Immediately at the end of the think-aloud interview ]
Central Contacts
- Li-Ting H. Longcoy312-996-3024
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Illinois Chicago | Chicago | Illinois | 60607 |
Find similar trials in Chicago, IL
By research site
Related Studies
- Registry Study for Radiation Therapy OutcomesRecruiting · Proton Collaborative Group · Scottsdale, Arizona
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsPHASE2/PHASE3 · Recruiting · Celgene · Birmingham, Alabama
- Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and MelanomaPHASE1 · Recruiting · Yana Najjar · Chicago, Illinois
- AnovaOS Network Powered Patient RegistryRecruiting · Anova Enterprises, Inc · Arlington Heights, Illinois